Syndax Pharmaceuticals Inc at JMP Securities Life Science Conference Transcript
All right, let's get started. So the next company we have is Syndax Pharmaceuticals and we have Michael Metzger, who is the President and Chief Operating Officer to present. Michael?
Great. Well, thanks, everybody. Thanks for having me, JMP. I appreciate the opportunity to speak with you all today. At Syndax, we are very passionate about developing new molecules for cancer and we bring that to work every day. This is our forward-looking statement. You can review it on our website.
We have a very deep pipeline of oncology agents who are focused on oncology, as I mentioned; three agents in multiple indications. It's actually a very exciting time for the Company to be in all of these indications. Today I will focus our presentation on entinostat in breast cancer and also 5613, which is our menin inhibitor. First in class, best in class, going into the clinic shortly.
The reason to focus on these two important programs -- entinostat in breast cancer and 5613 in acute
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |